On Tuesday, the Washington State Liquor and Cannabis Board (WSLCB) held its regularly-scheduled board meeting where they dropped a bombshell: a large quantity of marijuana infused edibles that have already been approved for production and sale in Washington will no longer be approved. When this new...

The Drug Enforcement Administration (DEA) announced last Friday that certain Food and Drug Administration (FDA)-approved drugs that contain cannabidiol (CBD) are properly rescheduled as Schedule V drugs under the Controlled Substances Act (CSA). While this move is far from categorically rescheduling CBD – as only...

As you may be aware, Cultiva Law is committed to advancing social justice issues as well as representing the cannabis industry, and one of Cultiva Law's primary issues of focus from a policy standpoint is easing the process by which people can vacate qualifying criminal records,...

Cultiva's own Aaron Pelley was recently featured in the Spokesman-Review for his selection as a Featured Speaker at this year's upcoming Seattle Hempfest. Aaron Pelley will be featured at Hempfest's 27th annual "protestival" held in Myrtle Edwards Park and Elliot Bay Park on August 17, 18, and 19, 2018....

By: Sam Mendez, Strategic Legal Counsel at Cultiva Law Canada made headlines last week when the Canadian Senate voted 52-29 to pass Bill C-45, permitting personal use and commercial production of cannabis. Prime Minister Justin Trudeau made clear he would legalize cannabis should he be elected Prime Minister during...

By: Sam Mendez, Strategic Legal Counsel at Cultiva Law Cannabis policy and politics continue to evolve on both state and federal levels and, in the Trump era, it is not uncommon to experience unexpected and even conflicting developments. Conservative Republican former Speaker of the House John Boehner joins a...

Last Thursday, the White House announced it is launching a multimillion-dollar ad campaign intending to warn young people about the dangers of opioid abuse and curb opioid addiction. It is part of the anti-opioid initiative President Trump announced in March of this year, following his...

Contact Us For A Consultation

Call (888) 896-3313 or fill out the form below: